The Priority Review

Tag

SBS

1 story

  1. Policy

    Scinai reports 167% revenue growth in first nine months of 2026

    Scinai Immunotherapeutics Ltd. reported revenue of $2.8 million for the nine months ended September 30 2026, up 167% from $1.05 million in the same period last year. The company cited expansion of its CDMO business, including the Yavne operations acquired on February 16 2026, as the primary driver of the increase.